Lucía Teijeira

Functional systemic <scp>CD</scp> 4 immunity is required for clinical responses to <scp>PD</scp> ‐L1/ <scp>PD</scp> ‐1 blockade therapy

Miren Zuazo, Hugo Arasanz, G. Fernández-Hinojal et al. · EMBO Molecular Medicine · 2019 · 211 citations · Full text

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

Ana Bocanegra, G. Fernández-Hinojal, Miren Zuazo-Ibarra et al. · International Journal of Molecular Sciences · 2019 · 73 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Pd-l1 Expression +15

The EORTC quality of life questionnaire for patients with colorectal cancer: EORTC QLQ-CR29 validation study for Spanish patients

Juan Ignacio Arrarás, Javier Suárez, Fernando Arias de la Vega et al. · Clinical & Translational Oncology · 2011 · 66 citations

Quality Of Life, Life Questionnaire, Life Assessment +8

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics

Hugo Arasanz, Miren Zuazo, Ana Bocanegra et al. · Cancers · 2020 · 65 citations · Full text

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

Hugo Arasanz, Ana Bocanegra, Idoia Morilla et al. · Cancers · 2022 · 35 citations · Full text

Cancer Immunosurveillance, Baseline Ldns, Medicine +14